Imaging of cholinergic terminals in the non-human primate brain using 18F-FEOBV PET: Development of a tool to assess cholinergic losses in Alzheimer's disease

2010 ◽  
Vol 6 (4) ◽  
pp. S286 ◽  
Author(s):  
Jean-Paul Soucy ◽  
Pedro Rosa ◽  
Gassan Massarweh ◽  
Antonio Aliaga ◽  
Esther Schirrmacher ◽  
...  
2006 ◽  
Vol 14 (7S_Part_5) ◽  
pp. P311-P312 ◽  
Author(s):  
Caitlin S. Latimer ◽  
Carol A. Shively ◽  
Dirk Keene ◽  
Matthew J. Jorgensen ◽  
Rachel N. Andrews ◽  
...  

2021 ◽  
Author(s):  
Kenya Sato ◽  
Hiiroki Sasaguri ◽  
Kumita Wakako ◽  
Yoiko Kurotani ◽  
Takeshi Inoue ◽  
...  

Abstract Aging is a primary risk factor of Alzheimer’s disease (AD), with the world-wide number of patients anticipated shortly to exceed 50 million. Despite extensive research efforts, no effective measures are available for its prevention or treatment due in part to a lack of human-like animal models. Here, we describe the generation of three mutant marmoset individuals in which exon 9 of the PSEN1 gene product is deleted (PSEN1-ΔE9); the ΔE9 mutations have been reported to cause early onset familial AD1-5. We used Transcription Activator-Like Effector Nuclease (TALEN) to delete the 3’ splice site of exon 9 in the marmoset PSEN1 gene; to this end, TALEN exhibits high genome-editing efficacy, generates few off-target effects, and produces minimal mosaicism. Indeed, whole genome sequencing and other analyses illustrated an inclusive absence of off-target effects and apparent absence of mosaicism. Fibroblasts obtained from newborns indicated occurrence of full-length presenilin 1 protein (PS1) caused by perturbation of PS1 endoproteolysis as well as an increased ratio of Aβ42/Aβ40 production, a signature of familial AD pathogenesis. To our knowledge, this is the first non-human primate model of familial AD. The model lines will be made available to the research community to facilitate the global fight against AD.


2020 ◽  
Author(s):  
Kenya Sato ◽  
Hiroki Sasaguri ◽  
Wakako Kumita ◽  
Takashi Inoue ◽  
Yoko Kurotaki ◽  
...  

SummaryAlzheimer’s disease (AD) is a major cause of dementia, with the number of patients with this condition anticipated to exceed 50 million worldwide in the near future. Despite extensive research efforts, no effective measures are available to facilitate the prevention or treatment of AD, which is due in part to a lack of animal models able to closely replicate a human-like disease state. Here, we describe the generation of three mutant marmoset individuals in which exon 9 of PSEN1 gene product has been deleted (PSEN1-ΔE9). Such ΔE9 mutations have been reported to cause early on-set familial AD (references1–5). We used Transcription Activator-Like Effector Nuclease (TALEN) to destroy the 3’ splice site of exon 9 in the marmoset PSEN1 gene. To this end, TALEN exhibits high genome-editing efficacy, generates few off-target effects, and produces minimal mosaicism. Indeed, whole genome sequencing and other analyses illustrated an absence of off-target effects and an apparent absence of mosaicism. Fibroblasts obtained from newborn marmosets exhibited uncleaved full-length presenilin 1 protein (PS1) caused by the perturbation of PS1 endoproteolysis as well as an increased ratio of Aβ42/Aβ40 production, a signature of familial AD pathogenesis. To our knowledge, this is the first non-human primate model of familial AD. We intend to make our marmoset model available to the research community to facilitate the global fight against AD.


2004 ◽  
Vol 165 (1) ◽  
pp. 283-297 ◽  
Author(s):  
Cynthia A. Lemere ◽  
Amy Beierschmitt ◽  
Melitza Iglesias ◽  
Edward T. Spooner ◽  
Jeanne K. Bloom ◽  
...  

2008 ◽  
Vol 4 ◽  
pp. T387-T387
Author(s):  
Rebecca F. Rosen ◽  
Harry LeVine ◽  
Lary C. Walker

Sign in / Sign up

Export Citation Format

Share Document